研究發現 基因測試可以讓許多乳腺癌患者避免化療大綱

The majority of women with a common form of breast cancer may be able to skip chemotherapy after surgery, based on their score on a genetic test, researchers said.

研究人員表示，基於在基因檢測中的得分，大多數患常見形式的乳腺癌的女性，可能可以在手術後跳過化療。

As many as 65,000 women in the United States alone could be impacted by the study, released at the American Society of Clinical Oncology annual meeting in Chicago.

美國臨牀腫瘤學會在芝加哥舉行的年度會議上公佈，僅美國就有65000名婦女會受到這項研究的影響。

"With results of this ground-breaking study, we now can safely avoid chemotherapy in about 70 percent of patients who are diagnosed with the most common form of breast cancer," said co-author Kathy Albain, an oncologist at Loyola Medicine.

研究的合著者、洛約拉大學醫學院的腫瘤學家凱西·阿爾班表示：“通過這項開創性的研究的結果，約70%的患有最常見乳腺癌類型的病人，可以安全地避免痛苦的化療過程。”

"For countless women and their doctors, the days of uncertainty are over."

“對於無數女性和她們的醫生而言，不明確的日子已經一去不復返了。”

A 21-gene test called Oncotype Dx that has been around since 2004 has helped guide some decisions, post-surgery. A high recurrence score, above 25, means chemo is advised to ward off a recurrence while a low score, below 10, means it is not.

一項名爲Oncotype Dx的21基因檢測自2004年以來一直在幫助指導手術後的一些決定。高於25的高復發評分意味着建議化療避免復發，而低於10分的低分則意味着不復發。

The current study involved more than 10,000 women and focused on those whose scores were in the middle range, from 11 to 25.

目前的研究涉及超過10000名女性，並關注那些分數在11-25分的中間範圍內的女性。

The results show that all women over 50 with a recurrence score of 0 to 25 can be spared chemotherapy and its toxic side effects.

結果顯示，50歲以上的復發評分爲0至25分的所有女性都可以免除化療及其毒副作用。

For women under 50 with a score of 0 to 15, chemo could be skipped.

對於50歲以下的0到15分的女性，可以跳過化療。

However, among younger women with scores 16 to 25, outcomes were slightly better in the chemotherapy group, so in those cases doctors may urge patients to consider a chemo regimen.

然而，在16至25分的年輕女性中，化療組的結果略好，因此在這些情況下，醫生可能會敦促患者考慮化療方案。

"The results should have a huge impact on doctors and patients. We are de-escalating toxic therapy." Albain said.

阿爾班表示：“結果應該對醫生和患者產生巨大的影響。我們正在逐步減少毒性治療。”